Seattle, WA. — July 21, 2020 — OTCQB: KNWN
Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, announced today that it has entered into a Research Agreement with Mayo Clinic to test and validate its patented Bio-RFID™ platform technology. Know Labs plans to first deploy its Bio-RFID platform in its wearable UBAND™ as a non-invasive Continuous Glucose Monitor (CGM).
Phil Bosua, Know Labs CEO, stated, “We are very pleased to work with Mayo Clinic. They bring a world-renowned reputation in diagnostics. We look forward to working with them during this research project as we continue the development of our non-invasive UBAND CGM.”
See About Know Labs, Inc. and our Safe Harbor Statement for company and regulatory information.